346 related articles for article (PubMed ID: 29462984)
1. Mathematical Modelling of Nitric Oxide/Cyclic GMP/Cyclic AMP Signalling in Platelets.
Kleppe R; Jonassen I; Døskeland SO; Selheim F
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462984
[TBL] [Abstract][Full Text] [Related]
2. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
3. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes.
Isidori AM; Cornacchione M; Barbagallo F; Di Grazia A; Barrios F; Fassina L; Monaco L; Giannetta E; Gianfrilli D; Garofalo S; Zhang X; Chen X; Xiang YK; Lenzi A; Pellegrini M; Naro F
Cardiovasc Res; 2015 Jun; 106(3):408-20. PubMed ID: 25852085
[TBL] [Abstract][Full Text] [Related]
5. Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.
Zhao CY; Greenstein JL; Winslow RL
J Mol Cell Cardiol; 2016 Feb; 91():215-27. PubMed ID: 26773602
[TBL] [Abstract][Full Text] [Related]
6. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
7. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
Degjoni A; Campolo F; Stefanini L; Venneri MA
J Thromb Haemost; 2022 Nov; 20(11):2465-2474. PubMed ID: 35950928
[TBL] [Abstract][Full Text] [Related]
8. Distinct phosphodiesterase 5A-containing compartments allow selective regulation of cGMP-dependent signalling in human arterial smooth muscle cells.
Wilson LS; Guo M; Umana MB; Maurice DH
Cell Signal; 2017 Aug; 36():204-211. PubMed ID: 28506928
[TBL] [Abstract][Full Text] [Related]
9. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Dickinson NT; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):371-7. PubMed ID: 9163326
[TBL] [Abstract][Full Text] [Related]
10. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions.
Wilson LS; Elbatarny HS; Crawley SW; Bennett BM; Maurice DH
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13650-5. PubMed ID: 18757735
[TBL] [Abstract][Full Text] [Related]
11. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling.
Mullershausen F; Friebe A; Feil R; Thompson WJ; Hofmann F; Koesling D
J Cell Biol; 2003 Mar; 160(5):719-27. PubMed ID: 12604588
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide.
Jensen BO; Selheim F; Døskeland SO; Gear AR; Holmsen H
Blood; 2004 Nov; 104(9):2775-82. PubMed ID: 15265792
[TBL] [Abstract][Full Text] [Related]
13. Novel roles of cAMP/cGMP-dependent signaling in platelets.
Smolenski A
J Thromb Haemost; 2012 Feb; 10(2):167-76. PubMed ID: 22136590
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent inhibitory effects of cGMP-analogues on thrombin-induced platelet-derived microparticles formation, platelet aggregation, and P-selectin expression.
Nygaard G; Herfindal L; Kopperud R; Aragay AM; Holmsen H; Døskeland SO; Kleppe R; Selheim F
Biochem Biophys Res Commun; 2014 Jul; 449(3):357-63. PubMed ID: 24845383
[TBL] [Abstract][Full Text] [Related]
15. Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation.
Wangorsch G; Butt E; Mark R; Hubertus K; Geiger J; Dandekar T; Dittrich M
BMC Syst Biol; 2011 Oct; 5():178. PubMed ID: 22034949
[TBL] [Abstract][Full Text] [Related]
16. PDE2 at the crossway between cAMP and cGMP signalling in the heart.
Weber S; Zeller M; Guan K; Wunder F; Wagner M; El-Armouche A
Cell Signal; 2017 Oct; 38():76-84. PubMed ID: 28668721
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide-induced changes in endothelial expression of phosphodiesterases 2, 3, and 5.
Schankin CJ; Kruse LS; Reinisch VM; Jungmann S; Kristensen JC; Grau S; Ferrari U; Sinicina I; Goldbrunner R; Straube A; Kruuse C
Headache; 2010 Mar; 50(3):431-41. PubMed ID: 19751368
[TBL] [Abstract][Full Text] [Related]
18. Collagen stimulation of platelets induces a rapid spatial response of cAMP and cGMP signaling scaffolds.
Margarucci L; Roest M; Preisinger C; Bleijerveld OB; van Holten TC; Heck AJ; Scholten A
Mol Biosyst; 2011 Jul; 7(7):2311-9. PubMed ID: 21597619
[TBL] [Abstract][Full Text] [Related]
19. Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5.
Jäger R; Schwede F; Genieser HG; Koesling D; Russwurm M
Br J Pharmacol; 2010 Dec; 161(7):1645-60. PubMed ID: 20698857
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
